Result of General Meeting and Completion of Fundraising and Strategic Collaboration with Phesi

Oxford, UK - 4 January 2021: Sensyne Health plc (AIM: SENS), the UK clinical AI company, announces that at the General Meeting held earlier today, the Resolutions proposed were duly passed by shareholders. The General Meeting was held to approve the proposed Placing, Subscription and Open Offer to raise £27.5 million through the issuance of 30,513,341 New Shares in the Company. In addition, the passing of the Resolutions means that the Strategic Collaboration between Sensyne Health and Phesi Inc, a US based specialist clinical trials data company, will become effective on 5 January 2021. 

The full text of the Resolutions can be found in the Notice of General Meeting set out in the shareholder circular published by the Company on 14 December 2020 which is available on the Company's website

It is expected that Admission of the New Shares will become effective at 8.00 a.m. on 5 January 2021. Following Admission, the Company will have 159,084,855 Ordinary Shares of 10p in issue each with equal voting rights. No shares are held in treasury.  

The above figure may be used by shareholders as the denominator for the calculations by which they will determine whether they are required to notify their interest, or a change to their interest, in the Company under the FCA's Disclosure Guidance and Transparency Rules.

Unless otherwise defined herein, capitalised terms used in this announcement shall have the same meanings as defined in the announcement of the Fundraising made by the Company on 08 December 2020.

For further information, please contact:

Sensyne Health plc



Lord (Paul) Drayson PhD FREng

Chief Executive Officer

T: +44 (0) 330 058 1845

Michael Norris

Chief Financial Officer





Peel Hunt LLP

Dr Christopher Golden

T: +44 (0) 207 418 8900

Nominated Adviser and Joint Broker

Oliver Jackson



Jock Maxwell Macdonald





Liberum Capital Ltd

Bidhi Bhoma

T: +44 (0) 20 3100 2000

Joint Broker

Euan Brown





Consilium Strategic

Mary-Jane Elliott

T: +44 (0) 77 0286 8207


Sukaina Virji



Davide Salve



 About Sensyne

Sensyne Health (AIM: SENS) is a healthcare technology company that creates value from accelerating the discovery and development of new medicines and improving patient care through the analysis of real-world evidence from large databases of anonymised patient data in collaboration with NHS Trusts. These anonymised patient data are ethically sourced in that any analysis of anonymised patient data (and hence the Company's access to it) must be pre-approved for each programme on a case-by-case basis by the relevant NHS Trusts. This is to ensure that the purpose of the anonymisation and the proposed analysis are subject to appropriate ethical oversight and information governance, including conformance with NHS guidelines, UK data protection law and applicable regulatory guidance. Sensyne Health is based in the Schrödinger Building in Oxford Science Park. For more information, please visit: 

Did you like this article?